Caristo was founded in 2018 by Cardiologists at the University of Oxford, following a decade of scientific research and technical development, to revolutionise diagnosis and treatment. With Care as one of our core values, we are committed to our mission of transforming health outcomes through clinical and scientific innovation.
While we have known for over 50 years that heart attacks are caused by inflammation in coronary arteries (which supply blood to the heart), clinicians have been unable to visualize and measure coronary inflammation with routine cardiac tests.
It is now possible to extract this information from any clinical CT heart scan with Caristo’s technology (known as CaRi-Heart®), allowing clinicians to prescribe effective, personalised treatments with our more comprehensive risk assessment tool.
CaRi-Heart® received CE mark, under the new MDR process, in February 2021 and is commercially available in Europe, UK, and Australia.
New products in the pipeline will also be capable of predicting stroke and diabetes risk, years in advance.
